Athira Pharma Inc logo

ATHA - Athira Pharma Inc Share Price

$10.71 1.1  11.2%

Last Trade - 22/10/21

Small Cap
Market Cap £290.5m
Enterprise Value £83.3m
Revenue £n/a
Position in Universe 4009th / 7261
Unlock ATHA Revenue
Relative Strength (%)
1m +5.89%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -69.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2021, Athira PharmaInc revenues was not reported. Net loss increased from$3.8M to $22.8M. Higher net loss reflects Research anddevelopment - Balancing increase from $2.2M to $18.9M(expense), General and administrative - Bal increase from$1.2M to $6.4M (expense), Stock-based Compensation in SGAincrease from $87K to $1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ATHA Revenue Unlock ATHA Revenue

Net Income

ATHA Net Income Unlock ATHA Revenue

Normalised EPS

ATHA Normalised EPS Unlock ATHA Revenue

PE Ratio Range

ATHA PE Ratio Range Unlock ATHA Revenue

Dividend Yield Range

ATHA Dividend Yield Range Unlock ATHA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ATHA EPS Forecasts Unlock ATHA Revenue
Profile Summary

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform, ATH platform and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. Its lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). The Company also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019 / ATH-1020 compounds, which are being advanced to address neuropsychiatric indications.

Last Annual December 31st, 2020
Last Interim June 30th, 2021
No. of Shareholders: 143
No. of Employees: 20
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 37,295,936
Free Float (0.0%)
Eligible for
ATHA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ATHA
Upcoming Events for ATHA
Wednesday 10th November, 2021
Athira Pharma Inc at Clinical Trials on Alzheimer’s Disease (CTAD) conference
Wednesday 10th November, 2021 Estimate
Q3 2021 Athira Pharma Inc Earnings Release
Wednesday 23rd March, 2022 Estimate
Q4 2021 Athira Pharma Inc Earnings Release
Frequently Asked Questions for Athira Pharma Inc
What is the Athira Pharma Inc share price?

As of 22/10/21, shares in Athira Pharma Inc are trading at $10.71, giving the company a market capitalisation of £290.5m. This share price information is delayed by 15 minutes.

How has the Athira Pharma Inc share price performed this year?

Shares in Athira Pharma Inc are currently trading at $10.71 and the price has moved by -46.72% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Athira Pharma Inc price has moved by -59.42% over the past year.

What are the analyst and broker recommendations for Athira Pharma Inc?

There are no analysts currently covering Athira Pharma Inc.

When will Athira Pharma Inc next release its financial results?

Athira Pharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Athira Pharma Inc dividend yield?

Athira Pharma Inc does not currently pay a dividend.

Does Athira Pharma Inc pay a dividend?

Athira Pharma Inc does not currently pay a dividend.

When does Athira Pharma Inc next pay dividends?

Athira Pharma Inc does not currently pay a dividend.

How do I buy Athira Pharma Inc shares?

To buy shares in Athira Pharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Athira Pharma Inc?

Shares in Athira Pharma Inc are currently trading at $10.71, giving the company a market capitalisation of £290.5m.

Where are Athira Pharma Inc shares listed? Where are Athira Pharma Inc shares listed?

Here are the trading details for Athira Pharma Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ATHA
What kind of share is Athira Pharma Inc?

Based on an overall assessment of its quality, value and momentum, Athira Pharma Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Athira Pharma Inc share price forecast 2021?

Shares in Athira Pharma Inc are currently priced at $10.71. At that level they are trading at 0.269% discount to the analyst consensus target price of 0.00.

Analysts covering Athira Pharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.685 for the next financial year.

How can I tell whether the Athira Pharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Athira Pharma Inc. Over the past six months, the relative strength of its shares against the market has been -45.18%. At the current price of $10.71, shares in Athira Pharma Inc are trading at -31.7% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Athira Pharma Inc PE Ratio?

We were not able to find PE ratio data for Athira Pharma Inc.

Who are the key directors of Athira Pharma Inc?

Athira Pharma Inc's management team is headed by:

Leen Kawas - PRE
Mark Litton - COO
Hans Moebius - OTH
Glenna Mileson - CFO
Barbara Kosacz - IND
Joseph Edelman - IND
John Fluke - IND
James Johnson - IND
Tadataka Yamada - NEC
Kevin Church - VPR
Rachel Lenington - CTO
Who are the major shareholders of Athira Pharma Inc?

Here are the top five shareholders of Athira Pharma Inc based on the size of their shareholding:

Perceptive Advisors LLC Private Equity
Percentage owned: 9.19% (3.43m shares)
Franklin Advisers, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.58% (2.08m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 5.11% (1.91m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.82% (1.80m shares)
VR Adviser, LLC Venture Capital
Percentage owned: 3.98% (1.49m shares)
Similar to ATHA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.